|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,268.10 INR | +0.86% |
|
-0.19% | +7.39% |
| 06-05 | Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments | MT |
| 06-04 | Lupin Limited Receives Approval from U.S. FDA for Ranluspec Ranibizumab Injection | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 10.88B | |||||
| 1,009B | |||||
| 560B | |||||
| 401B | |||||
| 328B | |||||
| 298B |
- Stock Market
- Equities
- 500257 Stock
- Charts Lupin Limited
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition